Summary by Moomoo AI
Apollomics Inc., a clinical-stage biopharmaceutical company, has filed an amendment to its Form F-3 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The Cayman Islands-based company, with operations in the U.S. and China, is preparing for the potential sale of securities to the public. The registration includes Class A ordinary shares and warrants, with the exact number and price yet to be determined. The securities may be sold from time to time in one or more offerings, and the proceeds are intended for general corporate purposes. This filing allows Apollomics to maintain an effective registration statement, facilitating future securities offerings. The company has not declared any cash dividends on its shares and does not anticipate doing so in the foreseeable future. Apollomics has obtained a 20-year tax concession from the Cayman Islands government, ensuring no tax on profits, income, gains, or appreciations. The company's Class A ordinary shares and warrants are listed on Nasdaq under the symbols 'APLM' and 'APLMW,' respectively.